P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)

N. Sugimoto(Osaka International Cancer Institute), Hiroshi Eguchi(The University of Osaka), Noriyuki Miyoshi(University of Shizuoka), Mamoru Uemura(Osaka International Cancer Institute), Yoshinori Kagawa(Osaka International Cancer Institute), Hirokazu Yamamoto(The University of Osaka), G. Sato(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Ken Konishi(Hyogo Prefectural Nishinomiya Hospital), Atsushi naito(Osaka Police Hospital), S. Yoshioka, Hideki Osawa(Osaka Hospital), Hiroshi Tamagawa(Otemae Hospital), Katsuki Danno(The University of Osaka), T. Shimokawa(Wakayama Medical University), M. Tei(Osaka Rosai Hospital), Ken Nakata(Sakai Municipal Hospital), N. Nishida(Osaka International Cancer Institute), H. Takahashi(The University of Osaka), Tatsushi Shingai(Kinki Central Hospital), K. Murata, Masaaki Miyo(Osaka National Hospital)
Annals of Oncology
June 1, 2022
Cited by 1


Related Papers